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The 35 Mb genome of Leishmania should be sequenced by late 2002. It contains approximately 8500
genes that will probably translate into more than 10 000 proteins. In the laboratory we have been piloting
strategies to try to harness the power of the genome–proteome for rapid screening of new vaccine candi-
date. To this end, microarray analysis of 1094 unique genes identified using an EST analysis of 2091
cDNA clones from spliced leader libraries prepared from different developmental stages of Leishmania
has been employed. The plan was to identify amastigote-expressed genes that could be used in high-
throughput DNA-vaccine screens to identify potential new vaccine candidates. Despite the lack of tran-
scriptional regulation that polycistronic transcription in Leishmania dictates, the data provide evidence
for a high level of post-transcriptional regulation of RNA abundance during the developmental cycle of
promastigotes in culture and in lesion-derived amastigotes of Leishmania major. This has provided 147
candidates from the 1094 unique genes that are specifically upregulated in amastigotes and are being used
in vaccine studies. Using DNA vaccination, it was demonstrated that pooling strategies can work to ident-
ify protective vaccines, but it was found that some potentially protective antigens are masked by other
disease-exacerbatory antigens in the pool. A total of 100 new vaccine candidates are currently being tested
separately and in pools to extend this analysis, and to facilitate retrospective bioinformatic analysis to
develop predictive algorithms for sequences that constitute potentially protective antigens. We are also
working with other members of the Leishmania Genome Network to determine whether RNA expression
determined by microarray analyses parallels expression at the protein level. We believe we are making
good progress in developing strategies that will allow rapid translation of the sequence of Leishmania into
potential interventions for disease control in humans.
Keywords: Leishmania; genome; vaccines
1. INTRODUCTION
Leishmaniasis remains a major public health problem
throughout the tropics. The current outbreak of kala-azar
or visceral leishmaniasis caused by Leishmania donovani
sensu strictu in eastern and southern Sudan has taken its
toll on an impoverished, war-stricken population, killing
tens of thousands and depopulating vast areas of southern
Sudan. The calamity brought kala-azar to the forefront as
one of the greatest epidemics of the 20th century (Perea
et al. 1989; De Beer et al. 1990). Post kala-azar dermal
leishmaniasis following drug treatment causes additional
problems, as do the dramatic and debilitating cutaneous
forms of disease that occur throughout tropical regions of
both the Old and New Worlds. Even in sub-tropical
regions where disease has not traditionally caused a major
problem in humans, sub-clinical status is elevated to clini-
cal disease in association with HIV infection (Rosenthal
* Author for correspondence (jennie.blackwell@cimr.cam.ac.uk).
†Present address: MRC UK Human Genome Mapping Project Resource
Centre, The Genome Campus, Hinxton, Cambridge CB10 1SB, UK.
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et al. 2000). There are no vaccines in routine use, and
chemotherapy still relies principally on antimonial-based
drugs first used in the early 20th century.
The 35 Mb genome of Leishmania should be sequenced
by late 2002. It contains approximately 8500 genes that
it is assumed will translate into more than 10 000 proteins.
The question is: how rapidly can we harness the power of
the genome–proteome to learn more about the biology of
the host–parasite interaction and to develop new drugs
and new vaccines? In our laboratory we have focussed on
DNA-vaccine technology to develop higher throughput
screens for potential new vaccine candidates. Initially the
following two questions were considered.
(i) Could we narrow down the number of genes to be
tested as vaccines by prescreening for genes
expressed in forms of the parasite that invade and
survive in the vertebrate host?
(ii) Could we test DNA vaccines in pools?
6 R. Almeida and others Genomes to vaccine in Leishmania
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Figure 1. Results of partition-based clustering of expression profiles for one experiment in which RNAs from different points
in the development cycle (days 3, 5, 7, 10 for promastigotes grown in Schneider’s insect medium) for L. major LV39. See § 2
for further description of the analysis.
2. EXPRESSION PROFILING USING cDNA
MICROARRAYS
The analysis of gene expression at the RNA level using
microarray techniques can provide a global genetic per-
spective on biological processes important in parasite sur-
vival and host–parasite interactions. In Leishmania, most
gene transcription is polycistronic. Transcript abundance
measured using microarray techniques will therefore
reflect post-transcriptional regulation of gene expression
through processes including regulation of mRNA stability.
The extent to which transcript abundance reflects ex-
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pression at the protein level has yet to be determined. The
first step was to determine whether significant differences
in transcript abundance could be measured at the RNA
level using microarray techniques.
In the sandfly vector, Leishmania undergoes develop-
mental changes that lead to the generation of infective
metacyclic forms transmitted to the vertebrate host. This
can be mimicked in culture as promastigote forms of the
parasite pass through logarithmic to stationary phases of
the growth cycle. To study the developmental changes in
transcript abundance, total RNA was prepared from
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promastigotes at days 3, 5, 7, 10 and 13 of culture and
from LAs for L. major LV39.
As a pilot microarrays were produced by spotting PCR-
amplified inserts from 2091 randomly selected full-length
cDNAs from spliced leader libraries prepared from differ-
ent developmental stages (days 3, 7 and 10 cultured pro-
mastigotes L. major LV39; LAs from L. major Friedlin)
(Coulson et al. 1996; Levick et al. 1996). These clones had
already been used for EST one-pass 5 sequence analysis
(Levick et al. 1996; R. Almeida, A. Norrish and J. M.
Blackwell, unpublished data). A complete list of the EST
sequences, and the cDNA libraries from which they were
derived, can be obtained at http://www.ebi.ac.uk/parasites/
leish.html. Sequence-cluster analysis shows that the 2091
genes represent 1094 unique transcripts, that is, there was
around 50% redundancy in the clones selected for ran-
dom-sequence analysis. For the clustering, a Blastn
analysis of all L. major ESTs against the original set
(Levick et al. 1996) in the dbEST database was perfor-
med. All hits with probabilities 1e10 were initially
ranked in descending order of quality. Sequences were
then placed in 1094 ‘pools’ (some contain only one entry)
on the basis of these data. Leishmania sequences with
potentially interesting Blast similarities to constituents of
the non-redundant nucleotide, dbEST or Swissprot pro-
tein sequence databases comprised 30% of the total EST
dataset. These hits represent the ‘top’ non-self hit
obtained for each sequence (the data have been parsed:
probability cut-off of 1e05). Out of these only 23% have
significant matches to genes of known functions such that
they can be assigned a putative function. Seventy percent
of the clones have no sequence identity to any other
sequences in the public databases. The 1094 unique genes
represent approximately 12% of the total estimated num-
ber of Leishmania genes.
To screen the microarrays, a single round of reverse
transcription was used to tag RNA transcripts for a parti-
cular developmental stage with Cy3. To compare changes
in transcript abundance across different developmental
stages tested on different microarray ‘chips’ we had to
decide on a control RNA that could be labelled with Cy5
and competitively hybridized with Cy3-labelled ‘test’
cDNA on every chip. In the initial experiment looking for
genes upregulated in expression in amastigotes (figure 1),
control RNA was used from a single time-point: day 5
cultured promastigotes of L. donovani LV9. More
recently, a pool of RNA across different developmental
stages was used for a single outgroup ‘control’ species; for
example, a pool of RNA from actively growing cultures
from days 3, 5 and 7 for L. amazonensis has been used
to compare changes in transcript abundance for different
developmental stages across L. donovani and L. major. Full
details of the results of these experiments will be presented
elsewhere (Almeida et al., unpublished data). All of
the data will be deposited in the public domain
(http://www.ebi.ac.uk/parasites/leish.html) with links that
will allow the data to be re-interrogated online at the Eur-
opean Bioinformatics Institute (http://www.ep.ebi.ac.uk/
EP/EPCLUST/). To compare changes in transcript abun-
dance across developmental stages the data were analysed
using both hierarchical and partition-based clustering
algorithms (Brazma & Vilo 2000) (http://industry.ebi.ac.
uk/~vilo/Expression-Profiler/). To understand how the
Phil. Trans. R. Soc. Lond. B (2002)
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Figure 2. Scatter plot showing fluorescence intensity on the
x- and y-axes for Cy5-labelled control RNA from the control
pool against Cy3-labelled RNA from L. major amastigotes.
The x- and y-axes have already been adjusted to eliminate
background fluorescence, so every spot on the graph is
expressed above the background. The individual points on
the scatter plot represent the 2091 independent clones on
the microarrays. The dotted lines above and below the ratio
1 : 1 line indicate the cut-offs for two-fold upregulation or
two-fold downregulation relative to the control pool. Two
dots are annotated to demonstrate that two clones may have
the same absolute fluorescence intensity on the Cy3
amastigote axis, but can be +2-fold and 2-fold relative
to the control pool.
clustering programs make such comparisons, it is useful
initially to look at a scatter plot for Cy3 against Cy5 spot
intensities for a single developmental stage within a single
experiment. Since we want to identify amastigote-
expressed genes for potential vaccine development, the
scatter plot for RNA harvested from LA of L. major LV39
(Cy3) against the L. amazonensis RNA pool (Cy5) is of
direct relevance (figure 2). Each spot on the scatter plot
represents a single cDNA clone. To declare a significant
change in transcript abundance between the developmen-
tal stages, the ratio of intensity of the Cy3 ‘test’
RNA : Cy5 ‘control’ RNA needs to be greater than +2 or
less than 2, that is, there needs to be more than a two-
fold enhancement or reduction in transcript abundance
comparing ‘test’ and ‘control’ RNAs. On the scatter plot
this includes the spots above and below the dotted lines.
It should be noted, however, that two different spots may
have the same absolute intensity for Cy3 (on the y-axis),
but one can show more than two-fold enhancement
(above the +2-fold dotted line) while the other can show
a more than two-fold reduction in intensity compared to
their respective Cy5 controls. This will be reflected differ-
ently in the patterns of changes in transcript abundance
that the cluster analysis will portray (cf. below). Spots that
fall within the two dotted lines do not differ significantly
in intensity from the control pool, and will cluster around
the ‘zero’ change line on the cluster analysis plots. Again,
many of the genes falling within this region will have high
absolute intensity on the Cy3 axis. Hence, if the question
is simply to ask which genes are expressed in amastigotes,
we might choose to set a cut-off on the Cy3 axis above
which all genes (= spots) will be considered to be
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Table 1. Identity of clones from clusters of genes upregulated in amastigotes of L. major relative to the day 5 promastigote control.
((a) The cluster depicted in figure 1e contains all the redundant copies of the tryparedoxin peroxidase gene; (b) the cluster
depicted in figure 1k contains six out of seven redundant clones of the nucleoside diphosphate kinase B gene. The output of
Epclust provides the clone name, accession number, and top matches and scores from Blast analyses, permitting identification
of clones coregulated with these genes.)
(a) tryparedoxin peroxidase cluster
6381 AA728310 32 5.90E-12 TR:O61000 Crithidia fasciculata tryparedoxin peroxidase
lmf030 T67356 32 l.40E-16 TR:O96763 Trypanosoma cruzi tryparedoxin peroxidase
lmh0l8 H64196 32 3.80E-40 TR:O61000 C. fasciculata tryparedoxin peroxidase
lmf030 T67356 32 1.40E-16 TR:O96763 T. cruzi tryparedoxin peroxidase
k085 AA680724 32 3.00E45 SW:TDX TRYBR T. brucei thioredoxin peroxidase
lm370 T93440 145 1.10E-65 SW:METKFLEIIN Leishmania infantum S-adenosylmethionine synthetase
lmk508 W88371 56 2.00E-32 TR:Q9N6Y7 L. major probable nucleoside diphosphate kinase B
021c A1034563 119 1.80E-27 TR:046368 Leishmania mexicana surface protein amastin
s033 AA680974 55 1. l0E-25 SW:IF51 SCHPO initiation factor EIF-5A-l
mb0l7 T67314 294 3.90E-11 SW:H2A PLAFA P. falciparum histone H2A
202c A1034553 294 7.70E-29 SW:H2A2 LEIDO Leishmania donovani histone H2A.2
lmk414 W88357 218 6.50E-31 TR:Q9N9A8 L. major possible ubiquitin fusion protein
515l AA728269 342 1.l0E-44 TR:P90633 Leishmania braziliensis elongation factor EF-lA
581m AA728297 187 3.40E-54 TR:Q9NE87 L. major hypothetical L3640.07
lmk271 W88395 162 2.90E-21 TR:Q9W3W8 Drosophila melanogaster CG3203 protein
lm393 T93450 311 3.50E-55 TR:O02498 L. major RPS7
362d AI034646 276 6.10E-20 TR:O97213 L. major L4830.9 protein
14 × 60S ribosomal proteins
13 × 40S ribosomal proteins
9 × other ribosomal proteins
66 × unknowns including lmd029 T67335 260 n.s. (1.0e  10)
(b) nucleoside diphosphate kinase B cluster
lmk4l0 AA060749 56 2.20E-57 TR:Q9N6Y7 L. major nucleoside diphosphate kinase B
168c AI034527 56 l.30E-47 TR:Q9N6Y7 L. major nucleoside diphosphate kinase B
lme0l4 T67339 56 7.70E-57 TR:Q9N6Y7 L. major nucleoside diphosphate kinase B
664c A1034834 56 6.60E-103 TR:Q9U1E1 L. major nucleoside diphosphate kinase B
q072 AA680908 56 4.40E-70 TR:Q9N6Y7 L. major nucleoside diphosphate kinase B
6531 AA728315 56 2.30E-26 TR:Q9N6Y7 L. major nucleoside diphosphate kinase B
438c M034692 82 2.20E-71 TR:Q9NK14 L. major mitotic centromere associated kinesin 2
214a AA741623 92 1.10E-25 SW:H4 CHLRE Chlamydomonas reinhardtii histone H4
292d AI034608 92 1.60E-17 TR:O62586 Blespharisma undulans histone H4
6831 AA728322 92 7.70E-13 TR:Q9U9A5 Leishmania tarentolae histone H4
4 × 60S ribosomal proteins
1 × other ribosomal proteins
7 × unknowns
expressed in amastigotes. The stringency of the cut-off
above this can be determined according to user require-
ments; for example, in the initial targeting of amastigote-
expressed genes as vaccine candidates we might choose to
set a cut-off a log-fold above the background. However,
since we cannot be sure that transcript abundance relates
directly to protein abundance, it might be prudent to sam-
ple and test genes with both high- and low-transcript
abundance.
To obtain an overall profile of the changes in transcript
abundance for each gene throughout the developmental
cycle we first used partition-based clustering asking the
clustering algorithm to cluster our 2091 genes around 10
‘seed’ clones that it chose as representative of the range
of different expression profiles. Figure 1 shows this analy-
sis for the experiment in which the different developmen-
Phil. Trans. R. Soc. Lond. B (2002)
tal stages for L. major LV39 were each compared against
day 5 L. donovani promastigote RNA. The 10 seeds are
shown in figure 1j. The program iteratively compares each
of the seeds to its next closest matching expression profile,
recalculating the cluster means or centres as it goes. The
final cluster centres are shown in figure 1l. The 10
resulting clusters are shown in figure 1a–i, k. The profiles
show log2 ratios for fold-increases above and below the
control RNA (log2 of the ratio 1 = 0). The biggest change
in expression relative to control for any genes within a
cluster are from log2 = 1 to log2 = +4 (figure 1b), that
translates to a 32-fold difference in relative abundance for
particular genes within the cluster between day 5 promas-
tigotes and amastigotes. The clusters in figure 1b,e,h,k are
of particular interest because they contain clusters of genes
that appear to be strongly upregulated in abundance in
Genomes to vaccine in Leishmania R. Almeida and others 9
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Figure 3. Key results from the DNA-vaccine experiments. (a) Typical results for lesion growth phenotypes in susceptible
BALB/c versus resistant CBA/Ca mice; (b) s.c. vaccination with 1 × 25 g lmd29 versus vector control; (c) results for
vaccination with pools (P1–P8) versus lmd29 and vector control, where P3 and P8 are significantly protected compared with
the vector; (d) the effect of vaccination with LmaR61, the DNA vaccine at the intersect of P3 and P8.
the amastigote stage of the parasite life cycle, and hence
might be good vaccine candidates. Looking within these
clusters, it can be seen that all redundant clones of the
tryparedoxin peroxidase gene fall within cluster 1e (table
1a), while six out of seven redundant clones of the nucleo-
side diphosphate kinase B gene fall within cluster 1i (table
1b). This is reassuring, since it demonstrates remarkable
within-experiment reproducibility that extends over all
redundant sets of clones within all of our experiments
(data not shown). We can then begin to ask questions
about what other genes that might be related in function
show parallel expression profiles. For example, genes
coregulated with nucleoside diphosphate kinase B include
histone 4 and the mitotic centromere associated kinensin
2 (table 1b). This is of interest given that highly conserved
homologues of nucleoside diphosphate kinase B occur
across prokaryote and eukaryote organisms. It is a dual-
action enzyme that maintains the intracellular level of 5-
nucleoside triphosphates (Gilles et al. 1991) and also acts
to regulate transcription (Postel et al. 1993). In Drosophila
it is known to regulate cellular differentiation and develop-
ment (de la Rosa et al. 1995). It also functions to regulate
transcription by the phosphorylation of transcription fac-
Phil. Trans. R. Soc. Lond. B (2002)
tors in a DNA-dependent manner (Lees-Miller 1996).
The enzyme is upregulated in Trypanosoma brucei during
the S phase of the cell cycle (Gale et al. 1994), indicating
that it plays some role in the cell cycle in trypanosomatids.
A more eclectic set of genes cluster with tryparedoxin per-
oxidase (table 1a), frustratingly including 66 genes of
unknown function that could relate to the antioxidant
pathway in which this gene plays a central role (Levick et
al. 1998; Tetaud & Fairlamb 1998; Alphey et al. 2000).
A more in-depth analysis of this cluster of unknown genes,
perhaps lowering the stringent cut-off originally set to
declare significant sequence identity, might reveal genes
of related function and importance. Experiments could
also be performed to determine which of these genes
responds to changes in experimentally induced oxidative
stress, thus helping to delimit which genes might contrib-
ute to antioxidant pathways.
3. FROM GENES TO VACCINES
The most direct route to taking our putative amastigote-
expressed genes into vaccine testing was to employ a
DNA-vaccine strategy. DNA vaccination has already
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proved successful in vaccinating mice against cutaneous
L. major infection (Gurunathan et al. 1997, 1998; Hand-
man et al. 2000; Fragaki et al. 2001). A number of experi-
ments (Norrish et al., unpublished data) have been carried
out in our laboratory to refine the DNA-vaccine strategy,
in particular to see whether it was possible to reduce both
the number and dose of vaccines given. This would facili-
tate a higher throughput of large numbers of potential vac-
cine candidates in a murine screen, and allow us to think
about pooling strategies to try to identify new vaccine can-
didates more efficiently. Figure 3 shows the results of one
such experiment. Figure 3a shows the normal profile for
L. major LV39 infection in susceptible BALB/c compared
with genetically resistant CBA/Ca mice. Figure 3b shows
that vaccination with 100 g vector DNA alone mimics
the BALB/c infection-only profile, whereas vaccination
with a single dose of 25 g DNA of a protective antigen
lmd29 (plus 75 g vector-only DNA) administered s.c.
6 weeks prior to challenge infection provides significant
protection. Figure 3c depicts the infection profiles for
eight pools of 4 × 25 g DNA for 16 unknown test vac-
cines from a 4 × 4 array. Two vaccine pools show some
protection relative to the vector-only control; the remain-
ing six pools gave the same infection profile, or showed
exacerbation of disease, relative to the vector-only control.
Figure 3d shows that the vaccine at the intersect of the
two protective pools, designated R61, is protective when
administered on its own. This strategy was therefore suc-
cessful in identifying a new vaccine candidate from the 16
test vaccines in the pools. However, it was also found that
protection was lost when 25 g lmd29 was administered
in a pool with 25 g each for three members of one of the
non-protective pools (data not shown). Hence, there may
be antigens within pools that exacerbate disease and mask
the potential protective effect of other members of the
pool. In current experiments this analysis is being
extended by testing the 20 pools obtained in a 10 × 10
array, alongside each of the 100 vaccine candidates tested
separately. One advantage of testing all the vaccine candi-
dates separately is that, with the full sequence of all the
vaccine candidates to hand, it will be possible to perform
a retrospective bioinformatic analysis to see if a predictive
algorithm can be devised for what constitutes a successful
vaccine candidate for leishmaniasis.
4. CONCLUSIONS
In the laboratory we have been piloting experiments
designed to see whether it is possible to develop global
approaches to identify amastigote-expressed genes and
carry out large-scale vaccine testing directly utilizing the
output of the genome project. The findings thus far have
been encouraging, but there is much work ahead to har-
ness the full power of the genome–proteome. In relation to
microarray analysis, it is necessary to determine whether
expression profiling at the RNA level bears any relation to
expression of the protein encoded by the RNA. To exam-
ine this we are working with other members of the Leish-
mania Genome Network to carry out parallel analyses of
developmental changes in the transriptome and the prote-
ome using material harvested from the same cultures of
parasites. We are also taking some of our protective anti-
gens to see if we can improve vaccine efficiency using a
Phil. Trans. R. Soc. Lond. B (2002)
DNA-vaccine prime and protein boost strategy (McShane
et al. 2001) employing attentuated Salmonella typhimurium
or Vaccinia virus as the protein-producing vaccine. Clearly
the real challenge will be to see how rapidly we can pro-
ceed from animal experimentation to phase I and II trials
in humans, thus proving the real worth that knowledge of
parasite genomes will probably prove to be in relation to
human health.
Laboratory work on parasite genome analysis and vaccine
development was supported by Glaxo Group Research Ltd,
the UNDP–World Bank–World Health Organization Special
Programme for Research and Training in Tropical Diseases
(TDR) the Commonwealth Scholarship Commission in the
UK, and the British Medical Research Council.
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